HopeStage
Back to all studies
CompletedNCT05414058

Methylphenidate added to treatment for schizophrenia-related thinking difficulties

About this titleRead the official source — NCT05414058
Medication studyAges 18–55Canada
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
OttawaSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 9, 2022
Recruitment status
Completed
Enrollment listed in the registry
35
Sponsor
The Royal Ottawa Mental Health Centre
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Canada
Age range
From 18 Years to 55 Years
Official registry ID
NCT05414058
Official title
Show the full official title

Adjunctive Methylphenidate Extended Release in Patients With Schizophrenia: a Single-centre Fixed Dose Cross-over Open-label Trial to Improve Functional and Cognitive Outcomes

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Ottawa

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is The Royal Ottawa Mental Health Centre.

Did this study involve medication?

Yes. The study involved medication, including Apo-Methylphenidate ER.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies